Amgen presents new data showcasing IMDELLTRATM

Amgen announced the presentation of new data showcasing IMDELLTRATM, a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager molecule, at the 2024 World Conference on Lung Cancer in San Diego. DeLLphi-303 Phase 1b Study Data in First-Line Maintenance Therapy: IMDELLTRA combined with a PD-L1 inhibitor as first-line maintenance therapy in ES-SCLC demonstrated a manageable safety profile with sustained disease control and positive survival outcomes. Key findings include: IMDELLTRA plus a PD-L1 inhibitor: demonstrated a positive benefit: risk profile with no new or unexpected safety findings; IMDELLTRA plus durvalumab: disease control rate of 62.5% and median duration of disease control that was Not Estimable; IMDELLTRA plus atezolizumab: DCR of 62.5% and median DoDC of 7.2 months; Following a median time of 3.5 months from first-line chemoimmunotherapy to first-line maintenance: IMDELLTRA plus durvalumab showed a 9-month overall survival of 91.8% and median progression-free survival of 5.3 months; IMDELLTRA plus atezolizumab showed a 9-month OS of 86.7% and mPFS of 5.6 months